Truist Securities Reiterates Hold on Inari Medical, Lowers Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Hold rating on Inari Medical (NASDAQ:NARI) and lowered the price target from $60 to $55.
July 31, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities has reiterated its Hold rating on Inari Medical and lowered the price target from $60 to $55.
The lowered price target from $60 to $55 by Truist Securities suggests a less optimistic outlook for Inari Medical, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100